Provided are oral modified release formulations comprising at least one benzimidazole compound. A preferred compound is the proton pump inhibitor omeprazole. In a preferred embodiment the formulation comprises particles containing omeprazole and having a polymer coating comprising methacrylic acid-ethyl acrylate copolymer, and particles containing omeprazole and having a release controlling polymer coating comprising methacrylic acid-ethyl acrylate copolymer and ammonio methacrylate copolymer.